IQIRVO takes flight at EASL

IQIRVO brings a new era of hope in PBC. As the first approved dual PPAR agonist for patients who don’t respond to or can’t tolerate UDCA, it represents transformation — a chance to do more for patients.

The booth was an oasis of calm in an attention-seeking congress hall. A scent-filled tulip garden enticed HCPs in. They simply picked up an iPad and were able to ‘see’ the digital butterflies. They were implored to ’catch’ the branded IQIRVO butterflies, each revealing key messages. The experience culminated in an elevator pitch and encouraged further engagement on the booth. There was plenty more to explore between the leave piece, key message video and photo opportunity, which used the vibrant hero image as the backdrop